StockVS

Koninklijke Philips N.V. (PHG) Analyse boursière

Santé

Koninklijke Philips N.V.

$26.94

$-0.01 (-0.04%)

Dernière mise à jour : 26 mai 2026

Historique des Prix

Analyse

Présentation de l'entreprise

Koninklijke Philips N.V. operates as a health technology company with a significant presence in North America, Greater China, and international markets, delivering solutions across Diagnosis & Treatment, Connected Care, and Personal Health segments. The firm functions within the Healthcare sector, specifically the Medical Devices industry, which focuses on the provision of diagnostic imaging solutions, ultrasound business units, and related medical equipment. This entity commands a substantial market capitalization of $25.67B, generating a total annual revenue of $17.83B while employing a workforce of 61,085 individuals. These valuation and revenue figures indicate that the company maintains a large-scale operational footprint, positioning it as a major player capable of sustaining extensive research and development efforts within the global medical device landscape.

Santé financière

The company reported a trailing twelve-month revenue of $17.83B, accompanied by a net income of $899.00M and an EBITDA of $2.02B, highlighting a substantial gap between top-line revenue and bottom-line profit that reveals a cost structure with significant operational expenses and taxes. The free cash flow stands at $453.00M, which demonstrates the company's ability to generate cash beyond capital expenditures, providing a degree of financial flexibility for debt servicing or capital allocation. Gross margin is recorded at 45.2%, indicating strong pricing power and efficient production costs relative to sales, while the operating margin of 10.7% reflects the efficiency of core business operations before interest and taxes. The profit margin of 5.0% shows the final percentage of revenue that translates into net earnings available to shareholders after all corporate expenses are deducted. On the balance sheet, total cash holdings of $2.79B are offset by total debt of $8.09B, resulting in a debt-to-equity ratio of 73.57%, which suggests a leveraged capital structure where debt obligations exceed equity capitalization. The current ratio is 1.32, indicating that the company holds sufficient current assets to cover its current liabilities, suggesting adequate short-term liquidity. Return on equity stands at 7.8% and return on assets is 3.2%, metrics that reveal the effectiveness of management in utilizing shareholder capital and total assets to generate profits, respectively.

Évaluation de la valorisation

The trailing twelve-month P/E ratio is 25.03, whereas the forward P/E is 12.84, implying that the market expects earnings growth that would bring the valuation multiple down over the coming year or that current earnings are depressed relative to future expectations. The price-to-book ratio is 2.01, indicating that the market values the company at more than twice its book value, which suggests a premium assigned to its intangible assets, brand equity, and growth prospects beyond its tangible net assets. Alternative valuation metrics include a price-to-sales ratio of 1.44 and an EV/EBITDA of 15.28, suggesting the company is trading at a moderate multiple relative to its sales and earnings power compared to historical averages for the sector. The stock's 52-week high is $33.44 and the 52-week low is $21.48, and without the current share price explicitly defined in the source data, the range indicates a trading band of approximately $11.96 where the stock has fluctuated over the past year. The beta value is 0.94, which means the stock's price volatility moves slightly less than the broader market, offering a risk profile that is marginally lower than the general market index.

Growth & Income

Revenue growth year-over-year is recorded at 1.1%, while earnings growth is listed as N/A, preventing a direct comparison of earnings expansion relative to revenue expansion but highlighting a period of stable rather than rapid top-line expansion. As a dividend payer, the company offers a dividend yield of 3.8% with a payout ratio of 91.7%, which indicates that nearly all net income is distributed to shareholders, raising questions about the sustainability of this payout given the specific earnings growth context. The high payout ratio combined with a static earnings growth figure suggests that the company relies on current earnings to fund the dividend rather than retained earnings for internal reinvestment. The overall growth and income profile presents a mature asset with modest revenue expansion and a high reliance on dividend distribution for shareholder returns rather than aggressive capital appreciation through retained earnings.

Comparaison avec les pairs

Koninklijke Philips N.V. (PHG) opère dans le secteur Dispositifs Médicaux. Voici comment il se compare à ses pairs les plus proches par capitalisation boursière :

Entreprise Ticker Cap. Boursière Ratio P/E
Koninklijke Philips N.V. PHG $25.66B 23.2
Abbott Laboratories ABT $150.96B 24.3
Stryker Corporation SYK $119.99B 36.2
Medtronic plc MDT $99.63B 21.7

Le ratio P/E moyen du secteur Dispositifs Médicaux est de 60.2x. Koninklijke Philips N.V. se négocie à un P/E de 23.2.

Cette analyse est générée par IA à titre informatif uniquement et ne constitue pas un conseil financier. Les données peuvent être retardées ou inexactes. Faites toujours vos propres recherches et consultez un conseiller financier qualifié avant de prendre des décisions d'investissement.

À propos de Koninklijke Philips N.V.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

La description de l'entreprise est affichée en anglais.

Visiter le site →

Statistiques Clés

Capitalisation
$25.66B
Ratio P/E
23.23
Plus Haut 52 Sem.
$33.44
Plus Bas 52 Sem.
$21.95
Volume Moyen
1.10M
Bêta
0.92
Rendement Dividende
3.76%

Données fournies par Yahoo Finance via yfinance. Mis à jour quotidiennement.

Info Entreprise

Bourse
NYSE
Pays
Netherlands
Employés
64,317